LXA4 significantly inhibits the expression of matrix remodeling genes.

Rajesh Kumar (72124), Anne-Catherine Clerc (526757), Ilaria Gori (526758), Ronan Russell (526759), Chiara Pellegrini (526760), Lerisa Govender (526761), Jean-Christophe Wyss (249968), Dela Golshayan (1503082), Geraldine O. Canny (492710)
2015 · doi:10.1371/journal.pone.0089742.g004 · W6942017044
other OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-05 ⓘ

Lipoxin A4 treatment significantly reduced the expression of matrix remodeling genes like MMP-2, MMP-3, MMP-9, TGF-β1, TGF-β2, and TGF-β3 in mouse endometriosis lesions and peritoneal fluid cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-05 · read from full text ⓘ

The paper investigated how lipoxin A4 (LXA4) affects progression of de novo and established endometriosis in a mouse model, focusing on prostaglandin E2 production and estrogen signaling pathways. Using sham and vehicle versus LXA4-treated groups (10 mice per group) and qPCR of lesions and peritoneal fluid cells (PFCs) collected 21 days after induction, the authors found that LXA4 significantly inhibited the expression of multiple matrix remodeling genes, including MMP-2, MMP-3, and MMP-9 as well as TGF-β1 and TGF-β2 (and assessed additional targets). A key limitation described by the study design is the reliance on gene-expression measurements at a single time point. This paper is centrally about endometriosis — specifically, LXA4’s inhibition of matrix remodeling gene expression in mouse endometriosis lesions and PFCs.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A. MMP-2, B. MMP-3, C. MMP-9, D. TGF-β1, E. TGF-β2, F. TGF-β3, G. MMP-2, H. MMP-9, I. TGF-β1, J. TGF-β2 gene expression in lesions and PFCs. Ten mice were used per group (Sham, Veh-, LXA4-treatment) and sacrificed 21 days after endometriosis induction. Lesions and PFCs were collected for qPCR analyses. Data were normalized to GAPDH and presented as mean ± SEM (***p<0.001 compared to Veh; ζζ p<0.01, ζζζ p<0.001 compared to Sham).
Full text 672 characters · extracted from oa-doi-fallback · click to expand
Lipoxin A4 Prevents the Progression of De Novo and Established Endometriosis in a Mouse Model by Attenuating Prostaglandin E2 Production and Estrogen Signaling Figure 4 LXA4 significantly inhibits the expression of matrix remodeling genes. A. MMP-2, B. MMP-3, C. MMP-9, D. TGF-β1, E. TGF-β2, F. TGF-β3, G. MMP-2, H. MMP-9, I. TGF-β1, J. TGF-β2 gene expression in lesions and PFCs. Ten mice were used per group (Sham, Veh-, LXA4-treatment) and sacrificed 21 days after endometriosis induction. Lesions and PFCs were collected for qPCR analyses. Data were normalized to GAPDH and presented as mean ± SEM (***p<0.001 compared to Veh; ζζ p<0.01, ζζζ p<0.001 compared to Sham).

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T08:34:59.281429+00:00
License: CC0 · commercial use OK